Compare Accenture plc (ACN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Accenture plc vs Sanofi SA — how do they compare? Accenture plc trades at $181.5 (market cap $110.24B), while Sanofi SA trades at $43.58 (market cap $104.30B). The key difference: Accenture plc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| ACN | SNY | |
|---|---|---|
Market Cap | $110.24B | $104.30B |
Sector | Technology | Health |
52-Week High | $288.54 | $52.34 |
52-Week Low | $124.41 | $41.33 |
Enterprise Value | $108.45B | $124.19B |
Dividend Yield | 3.62% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $179.82, up 0.88% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 EPS of $3.80, beating estimates, and maintains solid fundamentals with a P/E of 14.36 and net margin of 10.66%. Recent partnerships with TEPCO and AlphaSense highlight its AI-driven growth initiatives, while cash flow from operations surged to $11.47B in 2025.
The outlook remains positive given consistent earnings beats and strategic AI investments, though risks include competitive pressures and market volatility. Analyst consensus is bullish with a $189.77 price target, suggesting upside potential. Investors should weigh robust cash generation against elevated valuation multiples and macroeconomic headwinds.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
